Strimpakos Alexios S, Syrigos Kostas N, Saif Muhammad W
Oncology Unit, Third Department of Medicine, University of Athens, Sotiria General Hospital, Athens, Greece.
JOP. 2012 Jul 10;13(4):345-8. doi: 10.6092/1590-8577/947.
Pancreatic cancer is a relatively rare malignancy with a very aggressive natural course, not restrained by the existing current treatments. At the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, the results of few phase I clinical studies on solid tumors and pancreatic cancer were presented. In particular, in the field of immunotherapy, a pilot phase I study tested for first time a carcinoembryonic antigen (CEA)-based vaccine (Abstract #2561) on patients with pancreatic adenocarcinoma and another one the optimal dose and efficacy of trabedersen, an inhibitor of tissue growth factor-beta 2 (TGF-β2) aiming to enhance antitumor immune responses (Abstract #4034). Other phase I studies explored the pharmacokinetic and pharmacodynamic properties of an oral gemcitabine pro-drug (LY2334737; Abstract #2554), or of the combination of gemcitabine with sirolimus (Abstract #3096) or the combination of gemcitabine with an inhibitor of mitogen-activated protein kinase (MAPK), extracellular signal-regulated protein kinase (ERK) (MEK 1/2; Abstract #4034).
胰腺癌是一种相对罕见的恶性肿瘤，其自然病程极具侵袭性，现有治疗手段难以遏制。在2012年美国临床肿瘤学会（ASCO）年会上，公布了几项关于实体瘤和胰腺癌的I期临床研究结果。特别是在免疫治疗领域，一项I期试验首次对胰腺癌患者测试了一种基于癌胚抗原（CEA）的疫苗（摘要#2561），另一项试验则针对旨在增强抗肿瘤免疫反应的组织生长因子-β2（TGF-β2）抑制剂曲贝替定的最佳剂量和疗效进行了测试（摘要#4034）。其他I期研究探讨了口服吉西他滨前体药物（LY2334737；摘要#2554）、吉西他滨与西罗莫司联合用药（摘要#3096）或吉西他滨与丝裂原活化蛋白激酶（MAPK）、细胞外信号调节蛋白激酶（ERK）抑制剂（MEK 1/2；摘要#4034）联合用药的药代动力学和药效学特性。
